Yi Bin Chen

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Biomarkers for acute GVHD: can we predict the unpredictable?
    Y B Chen
    Division of Hematology Oncology, Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Bone Marrow Transplant 48:755-60. 2013
  2. doi request reprint Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 19:981-7. 2013
  3. doi request reprint Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD
    Y B Chen
    Division of Bone Marrow Transplantation, Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Bone Marrow Transplant 48:598-603. 2013
  4. pmc Expression of CD30 in patients with acute graft-versus-host disease
    Yi Bin Chen
    Department of Hematology Oncology, Bone Marrow Transplantation Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 120:691-6. 2012
  5. ncbi request reprint Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 18:805-12. 2012
  6. pmc Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation
    Yi Bin Chen
    Department of Hematology Oncology, Division of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 15:1066-76. 2009
  7. doi request reprint Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients
    Yi Bin Chen
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    Leuk Lymphoma 51:789-96. 2010
  8. doi request reprint Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 53:e77-80. 2011
  9. ncbi request reprint Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience
    Matthew Ulrickson
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 15:1447-54. 2009
  10. doi request reprint Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia
    Andrew M Brunner
    Department of Hematology and Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
    Am J Hematol 88:642-6. 2013

Detail Information

Publications36

  1. doi request reprint Biomarkers for acute GVHD: can we predict the unpredictable?
    Y B Chen
    Division of Hematology Oncology, Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Bone Marrow Transplant 48:755-60. 2013
    ..With the recent progress summarized below, these goals may soon be realized...
  2. doi request reprint Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 19:981-7. 2013
    ..2 mg/kg versus 6.4 mg/kg) is not associated with significant differences in overall outcomes...
  3. doi request reprint Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD
    Y B Chen
    Division of Bone Marrow Transplantation, Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Bone Marrow Transplant 48:598-603. 2013
    ..85%), P=0.03. No differences were found in α4β7 expression in any CD4(+) T-cell subsets or naive CD8(+) T cells. This study adds to the evidence that α4β7 integrin is involved in lymphocyte trafficking in acute intestinal GVHD...
  4. pmc Expression of CD30 in patients with acute graft-versus-host disease
    Yi Bin Chen
    Department of Hematology Oncology, Bone Marrow Transplantation Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 120:691-6. 2012
    ..These results suggest that CD30 expression on CD8(+) T-cell subsets or plasma levels of soluble CD30 may be a potential biomarker for aGVHD. CD30 may also represent a target for novel therapeutic approaches for aGVHD...
  5. ncbi request reprint Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 18:805-12. 2012
    ..Our findings suggest that the use of 2 partially matched UCB units appears to be a suitable alternative for patients undergoing RIC HSCT without an HLA-matched donor...
  6. pmc Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation
    Yi Bin Chen
    Department of Hematology Oncology, Division of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 15:1066-76. 2009
    ....
  7. doi request reprint Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients
    Yi Bin Chen
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    Leuk Lymphoma 51:789-96. 2010
    ..In conclusion, patients who fail R-CHOP appear to benefit from ASCT, but they may have a worse prognosis compared to patients who fail CHOP alone...
  8. doi request reprint Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 53:e77-80. 2011
    ..Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection...
  9. ncbi request reprint Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience
    Matthew Ulrickson
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 15:1447-54. 2009
    ..Our data indicate that in patients with NHL undergoing ASCT, Bu/Cy has efficacy and toxicity comparable to that of other reported regimens...
  10. doi request reprint Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia
    Andrew M Brunner
    Department of Hematology and Oncology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
    Am J Hematol 88:642-6. 2013
    ..We conclude that increased BMI was independently associated with improved OS among older AML patients at our institution...
  11. doi request reprint Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Andrew M Brunner
    Bone Marrow Transplant Unit, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 19:1374-80. 2013
    ..Nonrelapse mortality was 3.7% at day +100 and 5.6% at 2 years. We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older...
  12. pmc Donor-derived second hematologic malignancies after cord blood transplantation
    Karen K Ballen
    Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 16:1025-31. 2010
    ..Second myelogenous malignancies of donor origin occur after double UCBT, suggesting that a search for donor origin should be performed in all patients with suspected relapse...
  13. pmc Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant
    Andrew A Lane
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Leuk Lymphoma 53:1130-6. 2012
    ..0037). Increased vigilance for symptoms of pneumonitis is warranted for patients with prior mediastinal radiation and for younger patients, and dose reduction may be considered for patients who would receive greater than 1000 mg of BCNU...
  14. ncbi request reprint Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Br J Haematol 160:608-17. 2013
    ....
  15. pmc Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation
    Caron A Jacobson
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Biol Blood Marrow Transplant 18:565-74. 2012
    ..There is no increased risk of relapse, suggesting that graft-versus-leukemia activity is maintained. Early reconstitution of B cells and NK cells may, in part, account for these findings...
  16. ncbi request reprint The expanding frontier of hematopoietic cell transplantation
    Thomas R Spitzer
    Department of Medicine, Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cytometry B Clin Cytom 82:271-9. 2012
    ....
  17. doi request reprint Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma
    Gregory M Cote
    MGH Cancer Center, Boston, Massachusetts 02114 2617, USA
    Biol Blood Marrow Transplant 18:76-83. 2012
    ..Although these outcomes are encouraging, longer follow-up is required and comparison with other traditional ASCT regimens used for patients with non-Hodgkin lymphoma (NHL) is warranted...
  18. ncbi request reprint Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis
    Andrew M Brunner
    Massachusetts General Hospital Harvard Medical School, Boston, MA, United States Dana Farber Cancer Institute, Boston, MA, United States
    Leuk Res 38:773-80. 2014
    ..50, P=0.03). Compared to clinical trial outcomes, CBF-AML survival is poorer in the general population, particularly among African Americans and the elderly, and in t(8;21) compared to inv(16) AML. ..
  19. pmc Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 122:1510-7. 2013
    ..039). Rituximab can prevent systemic corticosteroid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in a prospective randomized trial...
  20. pmc Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma
    Anna Colpo
    Department of Clinical and Experimental Medicine, Massachusetts General Hospital, Boston 02114, USA
    Oncologist 17:80-90. 2012
    ..We present a summary of developments in each of these areas...
  21. ncbi request reprint FLT3 inhibitor-induced neutrophilic dermatosis
    Amir T Fathi
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Blood 122:239-42. 2013
    ..FLT3 inhibition can lead to clinically distinct dermatoses, which suggests the effect of FLT3 inhibition on myeloid differentiation and a manifestation of a broader "syndrome" associated with this therapy. ..
  22. pmc Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation
    Corey Cutler
    Dana Farber Cancer Institute, Boston, MA
    Blood 122:3074-81. 2013
    ..We observed encouraging trends in efficacy, with accelerated neutrophil recovery (17.5 vs 21 days, P = .045), coupled with preferential, long-term engraftment of the dmPGE2-treated UCB unit in 10 of 12 treated participants...
  23. ncbi request reprint Primary effusion lymphoma
    Yi Bin Chen
    Dana Faber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 12:569-76. 2007
    ..The prognosis for PEL is poor, with a median survival time of around 6 months. As the exact molecular steps in HHV-8-driven oncogenesis are unraveled, it is hoped that more specific therapeutic targets will be revealed...
  24. pmc Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome
    Ami S Bhatt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    N Engl J Med 369:517-28. 2013
    ..It has been hypothesized that the cord colitis syndrome, a complication of umbilical-cord hematopoietic stem-cell transplantation, is infectious in origin...
  25. doi request reprint Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant
    Karen K Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 119:1972-80. 2012
    ..In this review, we discuss the rationale for donor choice and the need of phase 3 studies to help answer this important question...
  26. ncbi request reprint Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation
    Albert C Yeh
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    Biol Blood Marrow Transplant 20:730-4. 2014
    ..001). There was no difference in disease-free or overall survival. Our study suggests that urate oxidase can be safely administered during myeloablative conditioning and may reduce the incidence of acute GVHD...
  27. ncbi request reprint Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis
    Andrew M Brunner
    Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts, USA
    Cancer 119:2620-9. 2013
    ..The authors performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to assess 5-year overall survival (OS) in various patient age groups...
  28. doi request reprint Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial
    Philippe Armand
    Philippe Armand and Edie Weller, Dana Farber Cancer Institute David E Avigan, Beth Israel Deaconess Medical Center Yi Bin Chen, Massachusetts General Hospital, Boston, MA Arnon Nagler, Chaim Sheba Medical Center, Tel Hashomer Reuven Or, Hadassah Medical Center, Jerusalem Rinat Rotem Yehudar, CureTech, Yavne, Israel Steven M Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus Hillard M Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH Mark S Kaminski, University of Michigan, Ann Arbor, MI H Kent Holland, Northside Hospital Edmund K Waller, Winship Cancer Institute, Emory University, Atlanta, GA Jane N Winter and Leo I Gordon, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine Stephanie A Gregory, Rush Medical Center, Chicago, IL James R Mason, Scripps Clinic Edward D Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego John M Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA Joseph W Fay, Baylor Research Institute, Department of Internal Medicine
    J Clin Oncol 31:4199-206. 2013
    ..The reconstituting immune landscape after autologous hematopoietic stem-cell transplantation (AHSCT) may be particularly favorable for breaking immune tolerance through PD-1 blockade...
  29. ncbi request reprint Bleomycin-induced flagellate erythema
    Yi Bin Chen
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:898-900. 2007
  30. ncbi request reprint AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter
    Yi Bin Chen
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:3176-8. 2007
  31. doi request reprint Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
    Amir T Fathi
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Blood 120:4649-52. 2012
    ..2-HG decrease was more rapid with induction chemotherapy compared with DNA-methyltransferase inhibitor therapy. Our data suggest that serum or urine 2-HG may serve as noninvasive biomarkers of disease activity for IDH-mutant AML...
  32. ncbi request reprint The evolving landscape in the therapy of acute myeloid leukemia
    Grace L Peloquin
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA
    Protein Cell 4:735-46. 2013
    ....
  33. ncbi request reprint Enzastaurin
    Yi Bin Chen
    Dana Farber Cancer Institute, Massachusetts General Hospital, GRB 740, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Investig Drugs 17:939-44. 2008
    ..Enzastaurin is a novel antineoplastic and antiangiogenic agent that acts through inhibition of protein kinase C (PKC)...
  34. pmc B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma
    Matija Snuderl
    Department of Pathology, James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Surg Pathol 34:327-40. 2010
    ..The aggressive clinical behavior and combination of genetic abnormalities seen in these cases may warrant categorization as a separate entity in future classifications and call for novel therapeutic approaches...
  35. ncbi request reprint Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
    Amir T Fathi
    Center for Leukemia, Massachusetts General Hospital, Zero Emerson Place, Suite 118, Boston, MA, 02114, USA
    Curr Hematol Malig Rep 9:186-92. 2014
    ..Here, we discuss the current options for treatment of relapsed AML after HSCT including conventional chemotherapy, novel agents, donor leukocyte infusion, second allogeneic HSCT, and emerging therapies. ..